A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
About this study
The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com
- Condition
- Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Diseases
- Tested
- Empagliflozin 10 MG, Dapagliflozin 10 MG
- Sponsor
- Herlev and Gentofte Hospital
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 3
- Minimum age: 18 years
- Study condition: Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Diseases
- Adults aged 18 years or more
Exclusion 2
- Incapabability of giving informed consent
- Withdrawal of informed consent
Where
12 sites, 12 recruiting
Bispebjerg Hospital
Copenhagen, Denmark
Rigshospitalet
Copenhagen, Denmark
Herlev and Gentofte Hospital
Herlev, Denmark
Steno Diabetes Center Copenhagen
Herlev, Denmark
Nordsjællands Hospital
Hillerød, Denmark
Holbæk Sygehus
Holbæk, Denmark
and 6 more sites on ClinicalTrials.gov
Contact
-
Morten Schou, Professor
004540523920 morten.schou.04@regionh.dk
-
Daniel M. Christensen, MD, PhD
004526248546 dmc@dadlnet.dk
Potential match only. Final eligibility is determined by the study team.